Bioharvest Sciences vs C4 Therapeutics
Bioharvest Sciences and C4 Therapeutics are similar in size: $34.5m and $35.9m of revenue in their latest fiscal years. Bioharvest Sciences grew faster (37.0% against 1.0%). Bioharvest Sciences kept more of each dollar of sales as profit: a net margin of -32.3% against -292.1%. C4 Therapeutics carries less debt relative to equity (0.0% against 0.6%).
| Latest fiscal year | Bioharvest SciencesBHST, 2025 | C4 TherapeuticsCCCC, 2025 |
|---|---|---|
| Revenue | $34.5m | $35.9m |
| Revenue growth | 37.0% | 1.0% |
| Net income | −$11.1m | −$105m |
| Operating margin | -16.2% | -320.5% |
| Net margin | -32.3% | -292.1% |
| Return on equity | -83.2% | -44.4% |
| Free cash flow | −$9.6m | −$99.3m |
| Cash | $23.0m | $74.6m |
| Total debt | $149,000 | $0 |
| Debt to equity | 0.6% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $193,000 |
| Employees | — | 104 |
| Market value | $34.7m | $393m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 1 sales |